Angiogenesis News and Research

RSS

Angiogenesis is blood vessel formation. Tumor angiogenesis is the growth of new blood vessels that tumors need to grow. This is caused by the release of chemicals by the tumor.

Pharmacological manipulation of DKK1, DKK2 can treat various vascular diseases

Angiogenesis, the development of new blood vessels, is required during embryonic development and wound healing, as well as during disease processes such as tumor growth. The signals that direct angiogensis are incompletely understood, but could represent novel targets for the development of therapies that promote or inhibit this process.

12 Apr 2011

Pfizer to support immatics' IMA901 Phase III trial in advanced renal cell carcinoma

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that Pfizer has agreed to support its pivotal Phase III trial with IMA901, its therapeutic cancer vaccine for advanced renal cell carcinoma.

11 Apr 2011

Bayer, Regeneron initiate two VEGF Trap-Eye Phase 3 trials in Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that they have initiated the first of two Phase 3 clinical trials evaluating the efficacy and safety of VEGF Trap-Eye, an investigational new agent for the treatment of certain eye diseases, in the treatment of Diabetic Macular Edema.

8 Apr 2011

Navigator-3 gene plays a key role in liver development

Scientists of the Max Delbr-ck Center for Molecular Medicine Berlin-Buch have demonstrated for the first time that a gene regulating neuronal cell migration during embryogenesis also plays a role in the development of the liver.

7 Apr 2011

Circadian's VGX-100 neutralises VEGF-C and inhibits tumour growth in mouse models of human cancers

Circadian Technologies Limited today released data at the American Association for Cancer Research (AACR) annual conference in Orlando, Florida (U.S.A.) demonstrating that its lead anti-cancer therapeutic, VGX-100, significantly inhibits tumour growth and spread in a variety of different mouse models of human cancer.

7 Apr 2011

ImClone Systems initiates IMC-3C5 Phase 1 trial in patients with advanced solid tumours

Circadian Technologies announced today that its licensee ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, has advised that it has commenced the first Phase 1 clinical trial of its fully-human monoclonal antibody IMC-3C5.

6 Apr 2011

Zebrafish research suggests new drug targets and markers to help treat melanoma

Thanks to the zebrafish, there is new hope for people with melanoma, an aggressive skin cancer that is responsible for approximately 8,700 deaths each year in the United States.

5 Apr 2011

American Cancer Society awards 85 institutions with $49,213,000 for new research, training

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 132 national research and training grants totaling $49,213,000 to 85 institutions nationwide in the second of two grants cycles for 2011.

5 Apr 2011

Researchers develop new cancer treatment

Scientists from the School of Pharmacy at Queen's University Belfast and Almac Discovery Ltd have developed a new treatment for cancer which rather than attacking tumours directly, prevents the growth of new blood vessels in tumours, starving them of oxygen and nutrients, thereby preventing their growth.

5 Apr 2011

VisualSonics demonstrates Vevo LAZR imaging system at AACR conference

VisualSonics Inc., a leader in real time, in vivo, high-resolution micro-imaging systems and a wholly-owned subsidiary of SonoSite Inc., is demonstrating the recently announced Vevo LAZR Photoacoustics Imaging system at the American Association of Cancer Research's annual conference.

5 Apr 2011

New anti-angiogenic therapy can lead to tumour growth inhibition

Scientists from the School of Pharmacy at Queen's University Belfast and Almac Discovery Ltd, announce the first publication describing a potential new anti-angiogenic therapy based on a natural protein first discovered at QUB. Anti-angiogenics prevent the growth of new blood vessels in tumours and starve them of nutrients, leading to inhibition of tumour growth.

4 Apr 2011

Alnylam completes patient enrollment in ALN-VSP Phase I trial against liver cancer

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it has completed enrollment in its ALN-VSP Phase I multi-center, multinational, open label, dose escalation clinical trial.

1 Apr 2011

Genentech's Lucentis Phase III trials in DME meets primary endpoints

Genentech, a member of the Roche Group, announced today that the second of two Phase III trials evaluating Lucentis in patients with diabetic macular edema met its primary endpoint.

28 Mar 2011

AHA to honor BIDMC investigator for groundbreaking Vascular Biology research

Alterations in blood vessel dilation lie at the heart of coronary artery health: When vessels dilate, blood and oxygen supplies successfully reach the heart. When vessels contract, blood and oxygen are diminished, leading to coronary artery disease.

23 Mar 2011

Scientists receive £5million EU grant to identify gene targets for kidney cancer treatment

An international consortium led by scientists from the Cancer Research UK London Research Institute, The Royal Marsden Hospital and the Technical University of Denmark has been granted nearly £5million by the European Union to identify gene targets for personalised treatment for kidney cancer patients.

18 Mar 2011

Researchers update 'Hallmarks of Cancer' seminal review

Renowned cancer researchers Robert Weinberg, a Founding Member of Whitehead Institute, and Douglas Hanahan, Director of the Swiss Institute for Experimental Cancer Research have updated their seminal review, "Hallmarks of Cancer," which has influenced the study of cancer and the development of therapeutics for more than a decade.

17 Mar 2011

HGSI, FivePrime enter agreement to develop, commercialize FP-1039 for multiple cancers

Human Genome Sciences, Inc. and FivePrime Therapeutics, Inc. announced today that they have entered into an agreement to develop and commercialize FivePrime's FP-1039 product for multiple cancers.

17 Mar 2011

Updated NCCN Guidelines for Ovarian Cancer outline new treatment options for women

Although finding effective screening tools remains a priority, new treatment options for women with ovarian cancer, such as the ones outlined in the updated NCCN Guidelines for Ovarian Cancer, are vital to making steady progress against the disease according to Robert J. Morgan, MD, of City of Hope Comprehensive Cancer Center and chair of the NCCN Guidelines Panel for Ovarian Cancer.

16 Mar 2011

New study: Two peptide agent combination might block tumor growth

A new study suggests that combining two experimental anticancer peptide agents might simultaneously block formation of new tumor blood vessels while also inhibiting the growth of tumor cells.

15 Mar 2011

Sanofi-aventis, Regeneron announce results of VEGF Trap Phase III trial in second-line NSCLC

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced results from the Phase III VITAL trial evaluating the investigational agent aflibercept (VEGF Trap) for the second-line treatment of non-small cell lung cancer (NSCLC).

11 Mar 2011

Angiogenesis News and Research

Further Reading

Pharmacological manipulation of DKK1, DKK2 can treat various vascular diseases

Pfizer to support immatics' IMA901 Phase III trial in advanced renal cell carcinoma

Bayer, Regeneron initiate two VEGF Trap-Eye Phase 3 trials in Diabetic Macular Edema

Navigator-3 gene plays a key role in liver development

Circadian's VGX-100 neutralises VEGF-C and inhibits tumour growth in mouse models of human cancers

ImClone Systems initiates IMC-3C5 Phase 1 trial in patients with advanced solid tumours

Zebrafish research suggests new drug targets and markers to help treat melanoma

American Cancer Society awards 85 institutions with $49,213,000 for new research, training

Researchers develop new cancer treatment

VisualSonics demonstrates Vevo LAZR imaging system at AACR conference

New anti-angiogenic therapy can lead to tumour growth inhibition

Alnylam completes patient enrollment in ALN-VSP Phase I trial against liver cancer

Genentech's Lucentis Phase III trials in DME meets primary endpoints

AHA to honor BIDMC investigator for groundbreaking Vascular Biology research

Scientists receive £5million EU grant to identify gene targets for kidney cancer treatment

Researchers update 'Hallmarks of Cancer' seminal review

HGSI, FivePrime enter agreement to develop, commercialize FP-1039 for multiple cancers

Updated NCCN Guidelines for Ovarian Cancer outline new treatment options for women

New study: Two peptide agent combination might block tumor growth

Sanofi-aventis, Regeneron announce results of VEGF Trap Phase III trial in second-line NSCLC

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo